GYRE
Gyre Therapeutics, Inc. Common StockstockNASDAQ
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.30 | 2026-11-12 | +1.40% | -3.020 |
| 1M | 6.09 | 2026-10-19 | -28.41% | 2.376 |
| 3M | 7.15 | 2026-08-19 | -39.02% | 2.163 |
| 6M | 6.26 | 2026-05-19 | -30.35% | 1.473 |
| 1Y | 7.57 | 2025-11-19 | -42.40% | 1.582 |
| 2Y | 12.92 | 2024-11-19 | -66.25% | — |
| 5Y | 6.29 | 2023-11-01 | -30.68% | 1.578 |
Gyre Therapeutics, Inc. Common Stock (NASDAQ:GYRE) stock price today is $4.36, and today's volume is 466,629. GYRE is down 4.386% today. The 30 day average volume is 203,343. GYRE market cap is $477.21M with 109.45M shares outstanding.